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Abstract
Background: In 2014 only 50 % of multidrug-resistant tuberculosis (MDR-TB) patients achieved a successful
treatment outcome. With limited options for medical treatment, surgery has re-emerged as an adjuvant therapeutic
strategy. We conducted a systematic review and meta-analysis to assess the evidence for the effect of surgery as an
adjunct to chemotherapy on outcomes of adults treated for MDR-TB.
Methods: Databases and grey literature sources were searched using terms incorporating surgery and MDR-TB. No
language or publication type limits were applied. Articles published pre-1990, without a comparator group, or
reporting <10 surgical participants were excluded. Two-stage sifting in duplicate was employed. Data on
WHO-defined treatment outcomes were abstracted into a standardised database. Study-level risk of bias was
evaluated using standardised tools. Outcome-level evidence quality was assessed using GRADE. Forest plots were
generated, random effects meta-analysis conducted, and heterogeneity assessed using the I2 statistic.
Results: Of 1024 unique citations identified, 62 were selected for full-text review and 15 retained for inclusion. A
further four articles were included after bibliography/citation searching, and one additional unpublished manuscript
was identified, giving 20 articles for final inclusion. Six were meta-analyses/systematic reviews and 14 were primary
research articles (observational studies).
From the 14 primary research articles, a successful outcome (cured/treatment completed) was reported for 81.9 %
(371/453) and 59.7 % (1197/2006) in the surgical and non-surgical group respectively, giving a summary odds ratio
of 2.62 (95 % confidence interval 1.94–3.54). Loss to follow-up and treatment failure were lower in the surgery
group (both p = 0.01). Overall GRADE quality of evidence for all outcomes considered was “very low”.
Conclusions: This meta-analysis suggests that surgery as an adjunct to chemotherapy is associated with improved
treatment outcomes in MDR-TB patients. However, inherent limitations in observational study design, insufficient
reporting, and lack of adjustment for confounders, led to grading of the evidence as very low quality. Data on
rationale for surgical referral, subsequent outcomes and resource-limited settings are scarce, precluding
evidence-based recommendations on the suitability of surgery by patient characteristics or setting. It is hoped that
highlighted methodological and reporting gaps will encourage improved design and reporting of future surgical
studies for MDR-TB.
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Background
It is estimated that 20 % of previously treated TB cases and
3.3 % of new TB cases worldwide have multidrug-resistant
tuberculosis (MDR-TB), which is caused by bacterial
strains resistant to both the two major anti-tuberculosis
drugs, isoniazid and rifampicin [1]. In 2014, there were an
estimated 480,000 incident cases of MDR-TB and 190,000
people died of MDR-TB [1]. Extensively drug-resistant TB
(XDR-TB) is defined as MDR-TB with additional resistance
to any fluoroquinolone, and to any of the three second-line
injectables (amikacin, capreomycin, kanamycin). Individ-
uals with XDR-TB have been reported by 105 countries to-
date, and are estimated to account for 9.7 % of those with
MDR-TB [1].
Treatment for MDR- and XDR-TB currently entails
therapeutic regimens with much lower efficacy and much
greater toxicity than those used for drug-susceptible TB.
Recommended treatment requires at least 20 months of
therapy and in 2014 only 50 % of MDR-TB patients globally
had a successful treatment outcome compared to 86 % for
newly diagnosed drug susceptible disease. Even with the
discovery of bedaquiline and delamanid, the first anti-
tuberculosis drugs with new mechanisms of action to be
approved in over 40 years and the first drugs to be intro-
duced specifically for MDR-TB combination therapy [2–4],
access is limited and regimen effectiveness still remains
below that of drug susceptible disease [4, 5]. Increasing
drug resistance further limits the treatment options avail-
able to MDR-TB patients.
In the pre-chemotherapeutic era surgical procedures
were commonly used for management of tuberculosis.
Collapsing the lung by creation of an artificial pneumo-
thorax or by plombage was regarded as an effective way
to deal with lobes of affected, non-functioning lung.
With the advent of effective chemotherapy however it
soon became clear that medical therapy offered a super-
ior option and enthusiasm for surgical approaches
waned. In the current context of increasing drug resist-
ant TB with far less effective medical therapy there has
been an understandable resurgence of interest in the use
of surgery as an adjuvant therapeutic strategy. In con-
trast to earlier techniques, the dominant procedures in
the 21st century are resection of segments, lobes or
whole lungs, with collapse therapy much less used. Sur-
gical resection can debulk disease, reducing bacillary
load, and removing devitalised lung that acts as a sanc-
tuary site for resistant organisms, poorly penetrated by
drug therapies. However, removal of lung tissue reduces
pulmonary capacity and thus it is crucial that pre-
operative assessment takes account of the residual lung
function with which the patient will be left post-
operatively. Appropriate timing of surgery, before too
much of the remaining lung is affected by disease, and
selection of the procedure to maximize removal of non-
functioning tissue whilst minimizing removal of non-
diseased lung are key determinants of a successful surgi-
cal outcome.
Current treatment guidelines issued by the World
Health Organization (WHO) and US Centres for Disease
Control and Prevention suggest that surgical interven-
tions may be appropriate as an adjunct to chemotherapy
when skilled thoracic surgeons and good postoperative
care are available [6, 7]. Intensive chemotherapy prior to
surgery and postoperative chemotherapy for 12–24
months is also recommended [6, 7]. Iseman et al. estab-
lished criteria for surgical intervention in MDR-TB [8],
including (i) drug resistance so extensive that there is a
high probability of failure or relapse, (ii) disease suffi-
ciently localised that the majority of the disease can be
resected, with the expectation of adequate cardiopulmo-
nary capacity post surgery and (iii) sufficient drug activ-
ity to diminish the mycobacterial burden enough to
facilitate probable healing of the bronchial stump. There
is a specific window of opportunity for surgery, as it is
rarely an immediate choice upon MDR diagnosis, but is
also not suited as a last resort rescue therapy. Other
guidelines refer to surgery being used for localized dis-
ease, when drug resistance is extensive, and as an ad-
junct to chemotherapy after at least two months of
surgery with the completion of 12–24 months chemo-
therapy post operatively [6]. Guidelines emphasis the
importance of only offering surgery in areas where there
is sufficient local surgical expertise and adequate infec-
tion control available.
Systematic reviews on the application of surgery for
MDR-TB were last published in 2012 [9]; and 2013 [10].
To inform the 2015/16 revision of the WHO MDR-TB
treatment guidelines an updated systematic review was
required which included a widened, global search of
multiple international databases.
We conducted a systematic review and aggregated-
data meta-analysis to assess existing evidence for the ef-
fectiveness of surgery on the outcomes of patients with
MDR-TB.
Methods
Though the methods are summarized briefly below, the
full review protocol and PRISMA checklist are available in
the Additional file 1 and a summary of the study protocol
is registered on the prospective register of systematic
reviews (PROSPERO reference: CRD42015029501) [11].
Minor amendments were made to the original protocol
where clarity was required to ensure consistent interpret-
ation. These included searching Google Scholar rather
than Google and the exclusion of articles with fewer than
10 patients recruited in the surgery arm rather than
overall.
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Search strategy
A comprehensive search strategy based on the PICOT
framework was developed in consultation with WHO tech-
nical experts and following standard PRISMA guidelines
[12] (see Additional file 1). The population of interest was
defined as patients with microbiologically-confirmed MDR-
or XDR-TB. The research question explored surgery as an
adjunct to standard of care, therefore the comparator group
was defined as those patients who received second-line
chemotherapy including at least four drugs, and the inter-
vention was defined as surgery in addition to this standard
of care. The primary outcomes of interest, based on WHO
definitions, were: cure, treatment completion, death, lost-
to-follow-up, treatment failure, transfer out and relapse.
Since the routine use of regimens including at least four
such agents only became commonplace in the early 1990s,
database searches were limited to 1st January 1990 - 25th
September 2015 (the date of the database search).
We searched electronic health care databases, sources of
evidence-based reviews, guidelines, and grey literature,
using Pubmed (incorporating MEDLINE), Embase,
Cochrane CENTRAL (including CDSR, DARE, and HTA
database), WHO Global Index Medicus, WHO Clinical
Trials Portal, the Union World Conference on Lung Health
abstracts available on line from 2004 to 2014, OpenSIGLE
databases and Google Scholar - in accordance with the
specifications of each database. No language or publication
type limits were applied. The specific search terms and
Boolean operators used and information sources searched
to identify relevant literature are detailed in Additional file
1: Tables S1, S2 and S3.
Study selection and data extraction
Two-stage sifting in duplicate was employed. First, titles
and abstracts of papers identified were independently
screened for suitability for subsequent full text review based
on the following pre-determined eligibility criteria: (i) re-
cruitment of individuals with microbiologically confirmed
multidrug-resistant or extensively drug resistant pulmonary
tuberculosis, regardless of participant age, (ii) use of surgery
as treatment for MDR-TB, as defined in the research
PICOT, (iii) the reporting of data from a comparator group
as defined above, and (iv) the reporting of one or more of
the primary outcomes of interest (detailed below).
The following study designs were included: case series,
case control study, cohort study, randomised controlled
study, systematic review or meta-analysis. Narrative re-
views not adding new data or new analysis of data to the
existing body of knowledge, commentaries and mathem-
atical modelling studies were excluded. Other exclusion
criteria applied were studies with fewer than 10 partici-
pants receiving the intervention (surgery), any systematic
review superseded by an updated systematic review and
any study not in humans.
Potentially eligible publications identified at the title/
abstract sifting stage were subsequently subjected to full
text review by two investigators and those fulfilling the
eligibility criteria were included for data abstraction and
analysis. Data were extracted from eligible papers into a
piloted, standardised database. Following methodology
described by the York ‘Centre for Reviews and Dissemin-
ation Guidance for Undertaking Reviews in Health Care’,
data extraction was conducted by one reviewer, and in-
dependently checked for accuracy by a second [13]. Un-
resolved disagreements in sifting or extraction were
resolved by a third, independent reviewer. Citation scan-
ning and bibliography searching was conducted for all
included articles to identify any further eligible articles.
Assessment of bias
Risk of bias was assessed at the study level using the
Cochrane Collaboration Tool [14] for prospective cohort
studies, the Downs and Black tool for retrospective co-
hort studies [15], and the AHRQ (Agency for Healthcare
Research and Quality) tool for systematic reviews [16].
An adjustment was made to the Downs and Black tool
such that power was interpreted as “reported” or “not
reported” and incorporated with the “reporting” sub-
scale. An assessment of quality of evidence for each key
outcome across studies was conducted using the Grad-
ing of Recommendations Assessment, Development and
Evaluation (GRADE) methodology [16, 17]. GRADE
analysis was conducted by two reviewers in tandem, with
a third for resolving discrepancies. Results were reported
following PRISMA guidelines.
Outcome measures
Primary outcomes of interest were as listed in the
PICOT, following WHO definitions [18]. Unsuccessful
outcomes included patients meeting the definitions of
death, loss to follow up (previously called default), treat-
ment failure, transfer out or relapse. The secondary out-
come of interest was adverse events (AE) from MDR
treatment and surgery. Outcomes were recorded as re-
ported by each study.
Analysis
Meta-analysis was used to combine results from studies
to obtain a summary odds ratio (OR), comparing surgery
versus non-surgery. The variance of the log OR was cal-
culated using Woolf ’s method, or from a transformation
of the OR and 95 % confidence interval (CI) where only
these statistics were reported. Random effects models
were used to calculate summary ORs and the associated
95 % CIs, and Forest plots used to summarise data
graphically. For studies with zero or 100 % of patients
having the outcome in the surgery or non-surgery group,
0.5 was added to all cells to enable the variance of the
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log odds ratio to be estimated. We report a chi-square
test for heterogeneity based on a fixed effect and the I2
statistic to quantify the amount of heterogeneity be-
tween the studies. We considered a value of I2 between
30 and 60 % as an indication of moderate heterogeneity,
and >60 % an indicator of considerable heterogeneity
[19]. Publication bias was investigated using funnel plots
when at least 10 studies reported a given outcome.
All analyses were conducted in Stata version 13
(StataCorp LP, College Station, Texas).
Results
Sifting and study characteristics
A total of 1203 citation hits were retrieved from the litera-
ture search, and 1024 remained after removal of duplicates.
Of these, 962 were excluded by title and abstract sifting,
leaving 62 references deemed suitable for full text review.
Fifteen of these were retained for inclusion and a further
four articles were included after review of bibliographies in
addition to one further identified unpublished manuscript,
yielding a total of 20 articles for the final analysis (Fig. 1).
Six included articles were meta-analyses/systematic reviews
and 14 were primary research articles. Three of the six sys-
tematic reviews/meta-analyses specifically focused on the
comparison of outcomes in surgery compared to medicine
alone among MDR-TB patients [10, 20, 21].
Of the 14 articles presenting primary research, two
and 12 were prospective and retrospective cohort stud-
ies, respectively (Table 1). The study population for the
surgery group ranged from 7 to 77 patients (median 36
patients) and for the non-surgery group ranged from 41
to 1347 patients (median 162 patients). Eight articles re-
ported prevalence of XDR-TB in the study population,
which ranged from 5–100 %; 12 articles reported HIV
prevalence of the study population, which ranged from
0–14 %. Only four observational studies and one meta-
analysis report the numbers of study participants receiv-
ing each type of surgical procedure [21–25]. Leimane
[23], Dravniece [26] and Sklyuev [27] specified the exact
type of surgical intervention including lobectomy, seg-
mentectomy, pneumonectomy or endobronchial valves,
whereas the other original research articles included re-
ferred to the surgical intervention in more general terms
as a resection of localised lesions. However, none of the
observational studies report the outcomes of interest
stratified by surgical type and therefore an aggregated
meta-analysis stratified by surgery type was not possible.
Only three [23, 25, 26] of the 14 primary research arti-
cles/abstracts focussed specifically on the outcomes of
surgery as compared to medical treatment alone,
whereas 11 articles [22, 24, 27–35] studied the outcomes
of MDR-TB patients, a sub-group of which had under-
gone surgery.
Five studies conducted meta-analyses [10, 20, 21, 36, 37]
(the sixth was a systematic review without meta-analysis
[9]), with three including an individualised patient data
analysis [20, 21, 36]. All included studies were observa-
tional. The total number of pooled subjects included in
the analyses ranged from 4238 to 9153, and the pro-
portion of these subjects undergoing surgery was 5.5
Fig. 1 Flow chart summarising search results
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to 13.4 %. Reported ORs from pooled data for the ef-
fect of surgery on cure or successful treatment in
these meta-analyses ranged from 1.5 (95%CI 0.9–2.6)
[20] to 2.24 (95 % CI 1.68–2.97) [10].
Study outcomes
Results of the meta-analyses are presented in Table 2.
All 14 primary research articles contributed to the
WHO-defined successful outcome of cured or com-
pleted treatment; 81.9 % (371/453) and 59.7 %
(1197/2006) had successful outcomes in the surgery
and non-surgery group, respectively. The summary
OR comparing surgery versus non-surgery was 2.62
(95 % CI 1.94–3.54) [Fig. 2a]. There was weak evi-
dence for heterogeneity (p = 0.08) and the I2 statistic
was 37.3 % indicating moderate heterogeneity. There
was potential overlap in patients contributing to two
papers [31, 32] and so a sensitivity analysis was con-
ducted excluding the earlier paper [31]; the resulting
summary OR was 2.81 (95 % CI 2.07–3.81). Results
were similar when restricted to an outcome of cure;
five studies contributed to this analysis giving a
Table 1 Summary of the 20 studies included in the review
Author Year of
publication
Design Sample
size overall
Sample size
surgery/non
surgery
Country % Male Ageb XDR HIV
Dravniece
[26]
2009 rc 254 77/177 Latvia nr nr nr nr
Gegia [35] 2012 pc 380 37/343 Georgia nr nr 13 % 1 %
Karagoz
[34]
2009 rc 142 35/107 Turkey 100 % 39 nr nr
Keshavjee
[33]
2008 rc 608 56/552 Russia 83 % ~35 5 % 0.8 %
Kim [31] 2007 rc 211 63/148 South Korea 59 % 37 20 % 0 %
Kim [32] 2008 rc 1407 60/1347 South Korea 74 % 43 5 % 5 %
Kwak [30] 2015 rc 123 18/105 South Korea 56 % 37 21 % 0 %
Kwon [22] 2008 rc 155 35/120 South Korea 53 % 40 17 % 0 %
Leimane
[23]
2005 rc 204 19/185 Latvia 77 % 43 (m);
39 (f)
nr 0.5 %
Mitnick
[24]
2008 rc 48 7/41a Peru 65 % 32 100 % 0 %
Shean [29] 2008 rc 491 28/463 South Africa 59 % nr nr 9 %
Sklyuev
[27]
2013 pc 102 49/53 not described nr nr nr nr
Tahaoglu
[28]
2001 rc 158 36/122 Turkey 87 % 42 (po);
36 (so)
0 % 0 %
Torun [25] 2007 rc 252 66/186 Turkey 81 % 38 nr nr
Ahuja [36] 2012 ma 9153 499/8654 23 countries 69 % 39 0 % 14 %
Falzon
[20]
2013 ma 6724 373/6351 Multiple countries 69 % 40 6 % 11 %
Fox [21] unpublished ma Canada; USA; Taiwan; Korea; Japan;
Estonia; UK; France
62 % (s);
70 % (ns)
37 (s);
39.4
(ns)
8.6 %
(s);
5.1 %
(ns)
nr
Johnston
[37]
2009 ma nr nr Canada 69 % 40 nr nr
Kempker
[9]
2012 sr 3218 (by
calculation)
312/2906 (by
calculation)
Korea, Turkey, Russia, Latvia, USA nr nr nr nr
Marrone
[10]
2013 ma 5284 706/4578 Canada; USA; South Africa; Germany;
Spain; Netherlands; South Korea; Turkey;
Russia; Latvia; Peru; Argentina; Japan
70 % 40 Nr nr
rc retrospective cohort, pc prospective cohort, ma meta-analysis, sr systematic review (no meta-analysis), nr not reported, m male, f female, po poor outcome, so
successful outcome, s surgery, ns non-surgery
aXDR cohort only (MDR cohort has 603 patients [87 in the surgery arm and 516 in the non-surgery arm], outcomes not described)
bEither mean or median, unless stated
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summary OR of 3.03 (95 % CI 1.59–5.78) (Table 2).
The summary OR for death following surgery com-
pared to medical treatment was 0.82 (95 % CI 0.41–
1.63, 5 studies), 0.35 (95 % CI 0.15–0.81, 4 studies)
for loss to follow up and 0.38 (95 % CI 0.18–0.81, 5
studies) for those that failed treatment (Table 2,
Fig. 3a and b). A summary OR was not calculated for
the outcome of transferred out as only two studies
reported data on this outcome. The funnel plot
(Fig. 2b) for the analysis of successful outcome is not
sufficiently asymmetrical to raise serious concerns.
Few studies reported information pertaining to sub-
groups of a priori interest such as patients with HIV,
and none reported comparative effectiveness of sur-
gery versus a non-surgical comparator disaggregated
into these subgroups. Seven [23, 28–30, 32–34] of 14
articles included in this review discussed AEs due to
medication with only two of these [28, 34] providing
AE data stratified by drug. Amikacin use was associ-
ated with hearing loss in 22–31 %, cycloserine use
with psychosis in 3 % and with psychosis/depression
in 27 % while para-amino salicylic acid was associated
with gastrointestinal disturbance in 2–17 %. Four of
the included studies [24, 25, 28, 34] provided a range
of times at which surgery occurred after starting
treatment for MDR-TB. Surgery was undertaken a
median of 11.6 months after initiation of MDR treat-
ment in the study by Mitnick et al., and a mean of
7.6 months in that by Karagoz and colleagues while
surgery was undertaken after a mean of only
4.9 months in Torun et al. In the study undertaken
by Tahaoglu surgery was considered after 2 months
of MDR-TB treatment. Four studies [22, 24, 25, 34]
considered the complications of surgical intervention
which occurred in between 3 and 29 % of patients,
while two studies [22, 34] specified details of surgical
complications, which included surgical wound prob-
lems, empyema, bleeding, bronchopleural fistula,
pneumonia, post pneumonectomy syndrome, and
post-operative respiratory failure.
A sensitivity analysis was also conducted adding
back in studies that were excluded from the main
analysis presented here because they reported fewer
than 10 patients in the surgery group; these studies
were identified through having been included in earl-
ier published meta-analyses. An additional three
studies [38–40] were included in this post-hoc
analysis for which the summary OR for successful
outcome was effectively unchanged, being 2.52 (95 %
CI 1.91 - 3.32) (Table 2).
Study- and outcome- level risk of bias
The main body of available evidence was in the form
of retrospective cohort studies, which scored from 7
to 19 out of 27 (median 14) when assessed for qual-
ity; this was interpreted by the authors as moderate
overall quality (Table 3). Principal risks of bias arose
because of little or no adjustment made for con-
founding [24–31, 34], unreported follow up duration
or wide variations in follow up duration without
reporting or adjustment for variation [23–26, 28–
31], lack of outcome assessor blinding [22–35], po-
tential indication bias [22–35], insufficient reporting
of loss to follow up [28, 31], and uncertainty in
population representativeness [26, 28–31, 34].
Study-level quality of prospective cohort studies
was low [28, 35] due to lack of outcome assessor
blinding, failure to report timing of intervention with
respect to study start, and potential indication bias
(Table 4).
Inclusion/exclusion criteria within the 14 included
cohort studies were mostly broad, therefore should not
Table 2 Summary of the meta-analyses for TB treatment outcomes
Outcome # studies % (n/N) surgery % (n/N) non-surgery Summary OR (95 % CI) P-value* P-value** I2
Successful treatment 14 [22–35] 81.9 % (371/453)a 59.7 % (1197/2006)a 2.62 (1.94, 3.54) <0.001 0.08 37.3 %
Successful treatmentb 13 [22–30, 32–35] 84.1 % (328/390)a 59.6 % (1108/1858)a 2.81 (2.07, 3.81) <0.001 0.1 30.8 %
Successful treatmentc 17 [22–35, 38–40] 81.7 % (379/464)a 59.2 % (1304/2199)a 2.52 (1.91, 3.32) <0.001 0.2 26.0 %
Cure 5 [22, 23, 25, 28, 34] 75.2 % (118/157) 54.9 % (308/561) 3.03 (1.59, 5.78) 0.001 0.07 54.2 %
Death 5 [22, 23, 25, 28, 34] 5.8 % (11/191) 7.2 % (52/720) 0.82 (0.41, 1.64) 0.6 0.8 0.0 %
Loss to follow-up 4 [22, 23, 25, 28] 3.8 % (6/156) 12.6 % (77/613) 0.35 (0.15, 0.81)d 0.01 0.7 0.0 %
Treatment failure 5 [22, 23, 25, 28, 34] 4.2 % (8/191) 11.4 % (82/720) 0.38 (0.18, 0.81) 0.01 0.99 0.0 %
Transfer out 2 [22, 23] 0 % (0/54) 2.0 % (6/350) Not analysed
aTwo studies only reported OR and 95%CI and so do not contribute to the denominator and numbers of outcomes reported in the table
bFrom a sensitivity analysis which excluded one study [31] for which there may be some overlap of patients also reported in Kim et al. 2008 [32]
cFrom a sensitivity analysis including three studies identified in Fox et al. which had <10 patients in the surgery arm. For two studies [39, 40] all patients in the
surgery group had a successful outcome and so 0.5 was added to all cells so that OR and 95 % CI could be calculated
dOne study [22] had zero patients lost to follow-up in the surgery arm, so 0.5 was added to all cells so that OR and 95 % CI could be calculated
*P-value for null hypothesis OR = 1; ** P-value for heterogeneity
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Fig. 2 a Forest plot for successful outcome using random effects meta-analysis (n = 14 studies). b Funnel plot for successful outcome using ran-
dom effects meta-analysis (n = 14 studies)
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have lead to significant biases in the included partici-
pants. Four of the studies did not provide any inclusion
or exclusion criteria, so it is not possible to assess these
for bias. One study excluded patients receiving less than
three months of treatment and two excluded HIV-
positive patients [22, 28, 31], which may introduce some
bias or affect generalizability of the data.
Included systematic reviews [9, 10, 20, 21, 36, 37] scored
positively on an average of 6 of 11 AHRQ criteria (range,
2–10) (Table 5). In general, reviews satisfactorily reported
the research question, searching/sifting strategy, statistical
methodology and drew conclusions supported by the data.
Data extraction was almost universally inadequately de-
scribed [9, 10, 20, 21, 36], only a third adequately assessed
study quality [10, 37], half lacked clarity in presentation of
results [9, 10, 36] and one third made no mention of dec-
larations of either funding sources or potential conflicts of
interest [10, 36].
Outcome level risk of bias assessed using GRADE
methodology was “very low” for all primary outcomes
with data available (Table 6). As all studies were ob-
servational, the maximum starting level for quality of
evidence for all outcomes in the GRADE system was
“low”; however, all outcomes were assessed to have
serious risk of bias and therefore downgraded to “very
low” quality of evidence due to indication bias and
limitations with respect to management of potential
confounders, representativeness of the enrolled popu-
lation and variation in follow up period. In the pooled
analysis, loss to follow up and treatment had strong
effect sizes, but according to GRADE methodology
the quality rating was not upgraded due to the
existence of serious risk of bias. There was serious in-
directness (defined as whether reported population,
intervention and outcomes align precisely with those
of interest) and imprecision (defined as when studies
have wide confidence intervals around the effect esti-
mate and when the study is insufficiently powered) in
the available evidence for death, due to heterogeneity
in definition (all-cause and TB-specific death), large
variation in follow up time and insufficient power to
detect an effect.
Discussion and conclusions
This meta-analysis of 14 observational studies indi-
cates a substantially increased likelihood of a success-
ful treatment outcome (cure or treatment completion)
in MDR-TB patients undergoing adjunctive surgery
(OR 2.62, 95 % CI 1.94–3.54). Restricting the outcome
of interest to cure reveals a similar effect size, albeit
with wider confidence intervals reflecting the smaller
number of contributing studies (5 studies, OR 3.03,
95 % CI 1.59–5.78).
The direction of this positive effect of surgery on
treatment success is consistent with previous reviews
by Marrone et al. [10] (OR 2.24, 95 % CI 1.68–2.97)
and Falzon et al. [20] (OR 1.5, 95%CI 0.9–2.6), albeit
with a marginally greater magnitude. A strength of
our review is the large number of globally-representative
databases searched, therefore the meta-analysis reported
here included a number of additional pre-2012 papers
and also included several more recently published
papers [20, 30].
Table 3 Risk of bias using the Downs and Black toola for retrospective cohort studies (n = 12 studies)
First author, year of publication Reporting
(maximum of 11)
External validity
(maximum of 3)
Internal validity, bias
(maximum of 7)
Internal validity,
confounding
(maximum of 6)
Total
(maximum of 27)
Dravniece 2009 [26] 3 0 2 2 7
Karagoz 2009 [34] 6 2 4 3 15
Keshavjee 2008 [33] 7 1 4 2 14
Kim 2007 [31] 7 0 2 1 10
Kim 2008 [32] 6 1 4 3 14
Kwak 2015 [30] 7 0 4 2 13
Leimane 2005 [23] 10 2 3 4 19
Mitnick 2008 [24] 5 2 4 2 13
Tahaoglu 2001 [28] 4 1 1 2 8
Torun 2007 [25] 8 1 3 2 14
Kwon 2008 [22] 9 2 3 4 18
Shean 2008 [29] 6 2 4 2 14
aTwenty-seven criteria are used to assess risk of bias. Each criterion is scored as Yes (1), No (0) or unable to determine (0). An overall score is calculated by
summation, as well as four sub-scales representing “reporting” (total of 11; includes power criterion), “external validity” (total of 3), “internal validity, bias” (total of
7) and “Internal validity, confounding” (total of 6). Higher scores represent lower risk of bias
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Fig. 3 a Forest plot for outcome of death using random effects meta-analysis (n = 5 studies). b Forest plot for outcome of loss to follow-up using
random effects meta-analysis (n = 4 studies)
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Adjunctive surgery was also associated with a reduc-
tion in loss to follow-up and treatment failure. For both
these analyses the estimated effects reported by individ-
ual studies all reported a reduction due to surgery. The
confidence intervals of the summary estimate for effect
of surgery on death (assessed as TB mortality or all
cause mortality) crossed the null (OR 0.82, 95 % CI
0.41–1.64), therefore there it was not possible to demon-
strate that surgery has an effect upon mortality.
Analyses were planned for several sub-populations,
including children, patients with diabetes, pregnant
women and patients with HIV, but either no relevant
data were identified or reporting was insufficient to
stratify for these subgroups. For patients with HIV, only
one meta-analysis [37] that included 12 studies with data
on HIV patients was identified; however, none of the
studies analysed the effect of surgery stratified by HIV
status. Only three of the 14 original research articles
clearly stated the type of surgery undertaken, the re-
mainder classified surgical intervention in more general
terms as resective surgery of localized lesions. As the
studies provided very limited, if any, information on the
type of surgery, sub-analyses comparing types of surgery
were not possible. Given the considerable difference be-
tween a pneumonectomy and a segmentectomy this
remains an important knowledge gap and unsatisfactor-
ily forces analyses into the binary surgery/non-surgery
approach which clearly conceals major heterogeneity in
procedures utilised.
As discussed recently by Roberts and Ker, the inclusion
of very small studies in systematic reviews can lead to an
exaggerated estimate of treatment effect due to publica-
tion bias and the tendency towards lower quality and
oversight [41]. Small case series often have less rigorous
inclusion criteria and are thus more prone to recruitment
bias. Therefore, in this review studies reporting fewer than
10 surgical cases were excluded. A sensitivity analysis in-
cluding such articles demonstrated that this had little ef-
fect on the effect estimates and did not affect the
conclusions. Two papers by Kim et al. [31, 32] had poten-
tially overlapping patients as two of the ten years reported
in the 2007 paper may have also been included in the
2008 paper. A sensitivity analysis to exclude the 2007
paper gave a similar effect estimate, demonstrating that
this potential overlap would not bias conclusions drawn.
Overall, the quality of evidence across each outcome
measure with available data was assessed as “very low”
using GRADE methodology. Most of the outcomes had
clear directionality and sufficiently narrow CIs to suggest
that surgery had a positive effect on patient outcomes,
Table 5 Risk of bias using the Agency for Healthcare Research and Quality tool for systematic reviews and meta-analyses (n = 6 studies)*
First author,
year of
publication
Study
question
Search
strategy
Inclusion and
exclusion
criteria
Interventions Outcomes Data
extraction
Study
quality
and
validity
Data
synthesis
and
analysis
Results Discussion Funding or
sponsorship
Marrone 2013
[10]
Yes Yes Yes Partial Partial Partial Yes Yes Partial Yes No
Kempker 2012
[9]
Yes No No No No No No No No Partial Yes
Ahuja 2012
[36]
Yes Yes Yes Partial Partial No Partial Yes Partial Yes Partial
Fox
(unpublished)
[21]
Yes No Yes Yes Yes No No Yes Yes Yes Yes
Falzon 2013
[20]
Yes Yes Yes No Partial No Partial Yes Yes Yes Yes
Johnston
2009 [37]
Yes Yes Yes No Yes Yes Yes Yes Yes Yes Yes
*Response of “Yes” indicates that the methodological issue was appropriately addressed/managed, “No” means the issue was not managed, and “Partial” indicates
the information required to make a judgement was unclear or partially reported
Table 4 Risk of bias using the Cochrane Collaboration tool for prospective cohort studies (n = 2 studies)a
First author, year
of publication
Sequence
generation
Allocation
concealment
Blinding of participants, personnel and
outcome assessors - primary outcome
Incomplete outcome
data - primary outcome
Selective
outcome
reporting
Other
sources of
bias
Gegia 2012 [35] Unclear Unclear No No No Yes
Sklyuev 2013 [27] Unclear Unclear No No No Yes
a Response of “Yes” indicates that the methodological issue was appropriately addressed/managed, “No” means the issue was not managed, and “Unclear”
indicates the information required to make a judgement was unclear or unavailable
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Table 6 Quality of evidence across studies for each key outcome using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology
Author(s): Harris, R; Khan, M and Allen, V
Date: 25/11/2015
Question: Surgery compared to no surgery for treatment of MDR or XDR TB
Setting: Georgia, Latvia, Russia, South Africa, South Korea and Turkey
Bibliography: Dravniece et al. (2009); Gegia et al. (2012); Karagoz et al. (2009); Keshavjee et al. (2008); Kim et al. (2007); Kim et al. (2008); Kwak et al. (2015); Kwon et al. (2008); Leimane et al. (2005);
Mitnick et al. (2008); Shean et al. 2008; Sklyuev et al. (2013); Tahaoglu et al. (2001); and Torun et al. (2007).
Quality assessment № of patients Effect Quality Importance
№ of
studies
Study design Risk of bias Inconsistency Indirectness Imprecision Other
considerations
Surgery No
surgery
Relative
(95 % CI)
Absolute
(95 % CI)
Cured (follow up: range 0.5 to 10 years; assessed with: WHO definition)
5 observational
studies
serious a,b,c,d,e,f,g not serioush not seriousi not serious nonej 118/157
(75.2 %)
308/561
(54.9 %)
OR 3.03
(1.59 to 5.78)
238 more per 1000
(from 110 more to
327 more)
⨁◯◯◯
VERY
LOW
CRITICAL
Successful outcome (follow up: range 0.25 to 7 years; assessed with: Cure or treatment success, WHO definition)
14 observational
studies
seriousa,b,c,d,e,f,g,k,l,m not seriousn not seriouso not serious nonej,p 371/453
(81.9 %)q
1197/2006
(59.7 %)
OR 2.62
(1.94 to 3.54)q
198 more per 1000
(from 145 more to
243 more)
⨁◯◯◯
VERY
LOW
CRITICAL
Death (follow up: range 0.5 to 10 years; assessed with: All-cause mortality or TB mortality)
5 observational
studies
seriousa,b,c,d,e,f,k,r,s,t not seriousn seriousu serioust nonej 11/191
(5.8 %)
52/720
(7.2 %)
OR 0.82
(0.41 to 1.64)
12 fewer per 1000
(from 41 fewer to
41 more)
⨁◯◯◯
VERY
LOW
CRITICAL
Loss to follow up (previously default) (follow up: range 0.5 to 10 years; assessed with: WHO definition)
4 observational
studies
seriousa,b,c,d,e,f,v not seriousn not seriousw not serious none j,x 6/156
(3.8 %)
77/613
(12.6 %)
OR 0.35
(0.15 to 0.81)y
78 fewer per 1000
(from 21 fewer to
105 fewer)
⨁◯◯◯
VERY
LOW
CRITICAL
Treatment failure (follow up: range 0.5 to 10 years; assessed with: WHO definition)
5 observational
studies
serious a,b,c,d,e,f,g,k not seriousn not seriousw not serious none j,x 8/191
(4.2 %)
82/720
(11.4 %)
OR 0.38
(0.18 to 0.81)
67 fewer per 1000
(from 20 fewer to
91 fewer)
⨁◯◯◯
VERY
LOW
CRITICAL
Transfer out (follow up: Not reported)
2 observational
studies
serious a,b,c,f,z,aa not serious ab not serious not seriousab none aa,ac 0/139
(0.0 %)
6/305
(2.0 %)
not estimable ⨁◯◯◯
VERY
LOW
Adverse Events from surgery (follow up: range 1.5 to 10 years)
1 observational
studies
serious a,b,f not serious ad not serious not seriousad publication
bias strongly
suspected ae
2/66 (3 %) surgical
patients died due to
surgical complications.
⨁◯◯◯
VERY
LOW
MD mean difference, RR relative risk
aDo not address or adjust for confounders and in some studies do not fully describe population - Dravniece et al. (2009); Karagoz et al. (2009); Kim et al. (2007); Kwak et al. (2015); Kwon et al. (2008); Mitnick et al.
(2008); Shean et al. (2008); Sklyuev et al. (2013); Tahaoglu et al. (2001) and Torun et al. (2007)
b Retrospective observational studies do not have randomisation and have inherent bias in who is offered surgery - Dravniece et al. (2009); Karagoz et al. (2009); Keshavjee et al. (2008); Kim et al. (2007); Kim et al.
(2008); Kwak et al. (2015); Kwon et al. (2008); Leimane et al. (2005); Mitnick et al. (2008); Shean et al. 2008; Tahaoglu et al. (2001) and Torun et al. (2007)
c Uncertainty in representativeness of study population - Dravniece et al. (2009); Karagoz et al. (2009); Kim et al. (2007); Kwak et al. (2015); Kwon et al. (2008); Shean et al. 2008; and Tahaoglu et al. (2001)
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d No estimate of variability given - Dravniece et al. (2009) and Tahaoglu et al. (2001)
e Number lost to follow up reported, but characteristics not described - Tahaoglu et al. (2001)
f Length of follow up not described or adjusted for in analysis - Dravniece et al. (2009); Kim et al. (2007); Kwak et al. (2015); Kwon et al. (2008); Leimane et al. (2005); Mitnick et al. (2008); Shean et al. (2008); Tahaoglu
et al. (2001); and Torun et al. (2007)
g In surgical studies, it is not possible to blind patients or study team. Outcome assessors could be blinded, and is somewhat important for assessing cure using smear as an outcome. However laboratory assessment
is generally conducted by different personnel than the diagnosing physician. For treatment success/failure there is a risk of reporting bias due to lack of blinding where data are programmatic, as there may be over-
reporting due to programmatic targets and could be biased by knowledge of surgical status
h Moderate I-squared (54.2 %) and overlapping CIs between studies so not downgraded
i Some variation in duration of follow up in outcome definition, however is not downgraded as alone this is not classified as serious issue for this outcome
j All studies are cohort, therefore may be some confounding due to patient allocation to surgery or no surgery. Patients who are more unwell may be more likely to be recommended for surgery (therefore causing
underestimate of effect size), however the most sick are often not offered surgery as they may be too unwell or disease too disseminated to allow surgery (therefore overestimating effect size). In addition, there may
be variation in the population offered surgery by setting or surgeon. As there is a specific window for surgery, these biases may have an impact on estimation of effect size, though it is unclear whether they would
bias the estimation in a particular direction, and are a reflection of the reality of the patient group offered surgery. Therefore, the reviewers decided not to upgrade or downgrade the rating
k Reports number, but not summary statistics or precision for this specific outcome - Leimane et al. (2005) and Mitnick et al. (2008)
l Abstract only, outcome and patient characteristics not clearly described - Dravniece et al. (2009)
m Loss to follow up not reported for surgical vs non-surgical patients - Kim et al. (2007)
n Low I-squared and overlapping CIs between studies, so not downgraded
o Most studies followed WHO outcome definitions. Some variation in duration of follow up to assess outcome but not downgraded as alone is not classified as serious issue for this outcome
p Empty lower right quadrant of funnel plot. However, it seems that smaller (less precise) studies are reporting lower effect estimate so if publication bias were to exist this would suggest the current estimate effect
measure is conservative. Per protocol, studies with <10 surgical participants were excluded, therefore the very smallest of studies were not included. Plot is not sufficiently asymmetrical to raise serious concerns, and
any bias would appear to cause an underestimate of effect, therefore quality not downgraded
q n= 13 for OR estimates, but n = 11 for numbers of patients summarised in the table, as 2 studies only report effect estimate rather than the number of patients with the outcome and the denominator
r In surgical studies, it is not possible to blind patients or study team. Outcome assessors could be blinded, but unimportant in mortality outcome as no subjectivity in assessment
s Time period of follow up very variable, and for patients with follow up for <2 years the follow up period is potentially insufficient for mortality outcome - Shean et al. (2008) and Torun et al. (2007)
t Pooled CIs cross the null. Event rate is low and post-hoc optimal information size calculation indicated number included in assessment of this outcome is too low to give sufficient power
u Variation between studies in outcome definition used (all-cause vs TB-only). Unclear/variable period over which death was assessed (e.g. died during treatment, within 6 months of completion, or after 2 years)
v In surgical studies, it is not possible to blind patients or study team. Outcome assessors could be blinded, but where data are programmatic they are unlikely to be. This could introduce underestimate in reporting of
default, but this bias is unlikely to vary between study groups
w Mostly use WHO definition, minor variation in definition in some studies, but sufficiently direct not to downgrade
x OR (similar to RR given infrequency of event) is <0.5 and the upper confidence interval would still provide a clinically significant benefit, therefore this would be considered a large effect size. However, the quality
are not upgraded as according to GRADE methodology this should not be done if the risk of bias is serious
y N = 2 studies had no patients lost to follow-up in the surgery group, so 0.5 has been added to all cells in order that a CI can be calculated. The summary OR restricted to the 2 studies that had at least one patient lost
to follow-up in each group is 0.47 (95 % CI 0.18, 1.24)
z Although reported separately, unlikely that clear differentiation has been made between LTFU and transfer out
aa Suspected underreporting of outcome, but uncertain as to how this would impact the conclusions
ab No pooled estimate, so insufficient evidence to assess
ac Only 2 publications, so not possible to assess publication bias, but given how few report this outcome publication bias may be plausible
ad One study and no comparator group so not possible to estimate
ae Likely that complications occurred in other studies, but have either not been reported or have been included in all-cause deaths
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with the exception of death for which the summary CIs
crossed the null. However, the event rate for death was
low and a post-hoc optimum information size calcula-
tion indicated that there was insufficient power. This
combined with the heterogeneity in the outcome defin-
ition suggest that the null result could conceivably be a
product of these methodological issues. Therefore the
reviewers are cautious to over-interpret the null result.
The most notable methodological issue is the absence of
experimental studies in the current body of evidence,
which thus consists entirely of observational studies
(mainly retrospective cohort studies). Reliance on such
study designs mean inherent biases such as lack of blind-
ing or randomisation cannot be managed, and residual
confounding is not managed through study design. The
most important limitation in the meta-analysis was the in-
ability to appropriately adjust for known confounding:
eight of the 12 retrospective cohort studies did not suffi-
ciently address confounding [24–26, 28–31, 34], which
could have a major influence upon the reported treatment
effects.
No studies explicitly evaluated the timing of surgery or
considered it as a confounding variable in a multivariate
regression, though two reported a wide range over which
surgery was performed [28, 34]. A window of opportunity
exists for indication of surgery, as those with less severe
disease tend to be allocated to medical treatment alone,
whereas in more severe disease there may be reticence to
operate owing to the risk of death or complications during
the procedure and the anticipated inadequacy of post-
surgery respiratory reserve. Although the timing of sur-
gery is highly likely to influence outcome, the available
data on this important confounding variable are scarce.
The experience of the surgeon and quality of surgical
facilities and post-surgical care likely affect estimation of
surgical risk in different settings. This, combined with
the lack of an evidence-based well-established guideline,
results in variation in the criteria used to determine
whether surgery is indicated. Since groups receiving sur-
gery are heterogeneous and their characteristics not well
reported, the authors propose the development of a
standardised minimum dataset for use by surgeons to
record their rationale for the surgery/no surgery decision
(e.g. clinical characteristics of lung involvement, safety
considerations), and for clearly recording the interven-
tion and patient outcomes. Incorporated in to an inter-
national registry (potentially online) this observational
data could quickly grow into an informative dataset to
help understanding of international practice, the drivers
of heterogeneity and practices more commonly associ-
ated with a more favourable outcome.
Studies were identified from Asia, Africa and Europe, so
provide some global representativeness, but were mostly
from relatively high income settings. Therefore, although
surgery was largely associated with positive outcomes in
the results reported here, caution is advised in generalising
this finding to more resource-constrained settings. Surgi-
cal expertise is a clear determinant of outcome and most
studies included in this meta-analysis were from well-
resourced tertiary referral centres. Clearly such low-
frequency surgery should be undertaken only in centres of
expertise; whether in low income settings the rates of
post-operative complications such as infection, pneumo-
thorax or other morbidities arising from less intensive
post-operative supervision would be different is not
known.
The paucity of reported adverse event data for both
medical and surgical arms also limit our conclusions.
Previously reported morbidity from surgery for MDR-TB
ranges between 9.4 to 46 % [42] while the frequent side
effects occurring during 2 years of anti-tuberculosis
treatment for MDR-TB are well documented [43]. Con-
sideration of surgical complication risk is an important
part of the decision-making process for surgeon and pa-
tient, though as surgery is an adjuvant not a replacement
therapy, patients who undergo surgical resection are not
spared any of the risk of drug therapy adverse effects to
which their non-surgical counterparts are also exposed.
This work indicates that the existing evidence, deter-
mined through the GRADE assessment as being of very
low quality, may support the use of adjuvant surgery in
the management of MDR-TB. However, due to poten-
tially important residual confounding, caution is advised
in the interpretation of these results. It is also self evi-
dent that surgery is not a sensible proposition for all
MDR-TB patients. The nature of patient and surgeon
decision-making about whether to proceed to surgery is
not at all well captured by this type of analysis nor by
the constituent articles, and remains a key obstacle to
the generation of unbiased evidence with minimal
confounding.
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